KBC Group NV reduced its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 20.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 104,323 shares of the medical research company’s stock after selling 26,562 shares during the period. KBC Group NV’s holdings in Amgen were worth $18,142,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in AMGN. Baker Ellis Asset Management LLC purchased a new position in shares of Amgen during the 3rd quarter worth about $108,000. Jackson Grant Investment Advisers Inc. lifted its holdings in shares of Amgen by 0.8% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares during the period. Phocas Financial Corp. purchased a new position in shares of Amgen during the 2nd quarter worth about $110,000. Omnia Family Wealth LLC lifted its holdings in shares of Amgen by 25.3% during the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares during the period. Finally, Salem Investment Counselors Inc. lifted its holdings in shares of Amgen by 4.7% during the 2nd quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after acquiring an additional 36 shares during the period. 79.53% of the stock is currently owned by institutional investors.
Several research analysts have recently weighed in on AMGN shares. BidaskClub upgraded shares of Amgen from a “strong sell” rating to a “sell” rating in a report on Saturday, December 2nd. Morgan Stanley cut their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating on the stock in a report on Friday, February 2nd. Vetr upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $181.60 price target on the stock in a report on Tuesday, February 27th. Oppenheimer restated a “buy” rating and issued a $205.00 price target on shares of Amgen in a report on Tuesday, January 30th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $191.26.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $169.43 on Monday. The stock has a market cap of $122,084.84, a P/E ratio of 13.47, a PEG ratio of 2.08 and a beta of 1.37. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 5.17 and a current ratio of 5.49.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.89 EPS. sell-side analysts forecast that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Stockholders of record on Thursday, May 17th will be paid a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 3.12%. Amgen’s dividend payout ratio is currently 205.45%.
Amgen announced that its board has initiated a share repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.
ILLEGAL ACTIVITY NOTICE: “KBC Group NV Has $18.14 Million Holdings in Amgen, Inc. (AMGN)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3301758/kbc-group-nv-has-18-14-million-holdings-in-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.